Table 4.
Multivariable analysesa of risk factors for sensory and motor symptoms of PN (EORTC QLQ-CIPN20) among ESBC survivors treated with a taxaneb. Estimates of relative risk and 95% confidence intervals are shown.
| Item# | Paclitaxel | Diabetes mellitusc | Age | BMI | Vibrating hand toolsc | Autoimmune diseasec,d | Cardiovascular diseasec,e | Alcohol risk consumptionc,f | Current smokingc |
|---|---|---|---|---|---|---|---|---|---|
| Sensory | |||||||||
| Tingling fingers/hands | 1.2 (1.1–1.4) | 1.3 (0.9–1.6) | NE | NE | 1.3 (1.1–1.7) | NE | NE | NE | NE |
| Tingling toes/feet | 1.3 (1.1–1.5) | 1.3 (1.1–1.7) | 1.2 (1.1–1.5) | 1.2 (1.1–1.5) | NE | NE | NE | NE | NE |
| Numbness fingers/hands | NE | 1.5 (1.2–1.8) | NE | NE | 1.3 (1.1–1.7) | NE | NE | NE | NE |
| Numbness toes/feet | 1.3 (1.1–1.5) | 1.3 (0.9–1.6) | 1.3 (1.1–1.6) | 1.2 (1.1–1.5) | NE | NE | NE | NE | NE |
| Shooting/burning fingers/hands | NE | 2.3 (1.6–3.3) | NE | 1.4 (1.1–1.9) | 1.5 (0.9–2.4) | NE | NE | NE | NE |
| Shooting/burning toes/feet | NE | 1.8 (1.3–2.5) | NE | 1.5 (1.2–2.0) | NE | NE | NE | NE | NE |
| Problems standing | 1.5 (1.1–2.0) | 1.5 (0.9–2.4) | NE | 1.6 (1.1–2.2) | NE | NE | 1.2 (0.9–1.6) | 0.9 (0.5–1.5) | NE |
| Difficulty hot/cold | 1.9 (1.1–3.2) | 3.8 (2.0–7.4) | NE | NE | NE | NE | 1.3 (0.8–2.4) | NE | NE |
| Hearing difficulty | NE | NE | 1.3 (1.1–1.6) | NE | NE | 1.4 (1.1–1.8) | NE | NE | NE |
| Motor | |||||||||
| Cramps in hands | NE | NE | 1.9 (1.5–2.4) | NE | NE | 1.9 (1.5–2.4) | NE | 0.5 (0.3–0.8) | NE |
| Cramps in feet | NE | NE | 1.2 (1.1–1.4) | NE | NE | NE | NE | NE | NE |
| Problem holding pen | NE | 2.4 (1.3–4.3) | NE | NE | NE | 1.9 (1.1–3.3) | NE | NE | NE |
| Difficulty manipulating small objects | 1.3 (1.1–1.5) | 1.3 (0.9–1.8) | 1.5 (1.2–1.8) | NE | 1.4 (1.1–1.9) | 1.3 (0.9–1.7) | NE | NE | 1.4 (1.1–1.8) |
| Difficulty opening a jar | NE | 1.4 (1.2–1.5) | 1.2 (1.1–1.3) | NE | NE | 1.3 (1.1–1.4) | NE | NE | NE |
| Difficulty walking/foot drop | NE | 2.3 (0.9–5.6) | NE | 2.3 (1.1–4.6) | NE | 2.5 (1.2–5.3) | NE | 0.8 (0.3–2.0) | NE |
| Difficulty climbing stairs | NE | 1.0 (0.7–1.5) | 1.6 (1.3–2.0) | 1.6 (1.2–2.0) | NE | NE | 1.0 (0.8–1.3) | 0.8 (0.6–1.2) | 1.6 (1.2–2.2) |
PN peripheral neuropathy, ESBC early-stage breast cancer, BMI body mass index, NE variable not entered in multivariable analyses.
Bold values shows significant relative risks.
aThe following variables were entered into the univariable analysis: type of taxane (docetaxel vs paclitaxel), age at diagnosis (<65 vs ≥65 years), BMI at diagnosis (<25 vs ≥25), receiving treatment for diabetes mellitus (no vs yes), use of vibrating hand tools at work (no vs yes), autoimmune disease (no vs yes), alcohol risk consumption (no vs yes), cardiovascular disease (no vs yes), current smoking (no vs yes), mastectomy (no vs yes) and lymph node metastases (no vs yes). Only predictive factors with a statistically significant association (p < 0.05) in the univariable analyses with an individual symptom were entered into the multivariable model.
bN = 628 treated with either docetaxel or paclitaxel. The 18 survivors treated with both docetaxel and paclitaxel were excluded from the analysis.
cSelf-reported at the time of completing the questionnaire.
dRheumatism, scleroderma, systemic lupus erythematosus and Sjogren’s syndrome.
eHypertension, heart failure, angina pectoris and myocardial infarction.
fAlcohol risk consumption measured by AUDIT-C.